Literature DB >> 8821684

International comparison of the community prevalence of symptoms of prostatism in four countries.

P P Sagnier1, C J Girman, M Garraway, Y Kumamoto, M M Lieber, F Richard, G MacFarlane, H A Guess, S J Jacobsen, T Tsukamoto, P Boyle.   

Abstract

We conducted an international comparison of the prevalence of urinary symptoms of prostatism in 4 countries, using a community-based random sampling of subjects, similar study procedures, and a single definition of cases that was based on a standardized symptom questionnaire. In Scotland 1,994 medically eligible men aged 40-79 years agreed to participate from 3 communities of the Forth Valley. In France, a nation-wide survey was conducted cross-sectionally in a representative sample of 2,011 French men aged 50-84 years. In the USA, the Olmsted County (OC) study recruited an age- and urban/rural-stratified random sample of 2,115 county residents drawn from medically eligible men aged 40-79 years. In Japan, 290 men aged 40-79 years from a fishing village participated in the study. Response rates were 55, 53, 55, and 43% in Scotland, France, OC and Japan, respectively. Urinary symptoms were assessed by the International Prostate Symptom Score (I-PSS), after metrologic validation in English and cross-cultural adaptation of the questionnaire. The prevalence of moderate to severe symptoms (I-PSS > 7) were 14, 18, 38, and 56% in France, Scotland, OC and Japan, respectively. This pattern was consistent within decades of age, and was found for most of the individual urinary symptoms. The proportion of men in Japan reporting very low I-PSS (0 or 1) was approximately 2, 4 and 8 times less frequent, than in OC, Scotland, and France, respectively. Differences in the prevalence of reported urinary symptoms might reflect between-country differences in the true prevalence of benign prostatic hyperplasia. However, cross-cultural differences in the perception and/or willingness to report urinary symptoms may play an important role in the observed differences. Further study will be required to elucidate the underlying causes of the observed differences.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8821684     DOI: 10.1159/000473711

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  15 in total

Review 1.  Tamsulosin: an update of its role in the management of lower urinary tract symptoms.

Authors:  Katherine A Lyseng-Williamson; Blair Jarvis; Antona J Wagstaff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  180-W XPS GreenLight laser vaporization for benign prostate hyperplasia: 12-month safety and efficacy results for glands larger than 80 mL.

Authors:  Bulent Altay; Bulent Erkurt; Murat Can Kiremit; Vahit Guzelburc; Mustafa Yucel Boz; Selami Albayrak
Journal:  Lasers Med Sci       Date:  2014-10-02       Impact factor: 3.161

3.  The prevalence of lower urinary tract symptoms in Austrian males and associations with sociodemographic variables.

Authors:  G Haidinger; S Madersbacher; T Waldhoer; G Lunglmayr; C Vutuc
Journal:  Eur J Epidemiol       Date:  1999-09       Impact factor: 8.082

4.  Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment.

Authors:  Peter Chang; Meredith M Regan; Montserrat Ferrer; Ferran Guedea; Dattatraya Patil; John T Wei; Larry A Hembroff; Jeff M Michalski; Chris S Saigal; Mark S Litwin; Daniel A Hamstra; Irving D Kaplan; Jay P Ciezki; Eric A Klein; Adam S Kibel; Howard M Sandler; Rodney L Dunn; Catrina M Crociani; Martin G Sanda
Journal:  J Urol       Date:  2016-09-02       Impact factor: 7.450

Review 5.  Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective.

Authors:  L M Eri; K J Tveter
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

Review 6.  Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.

Authors:  Christopher J Dunn; Anna Matheson; Diana M Faulds
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

7.  Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score.

Authors:  I Araki; S Kuno
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

Review 8.  Medical treatment of benign prostatic hyperplasia.

Authors:  Stephen S Connolly; John M Fitzpatrick
Journal:  Postgrad Med J       Date:  2007-02       Impact factor: 2.401

9.  Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer.

Authors:  Peter Chang; Konrad M Szymanski; Rodney L Dunn; Jonathan J Chipman; Mark S Litwin; Paul L Nguyen; Christopher J Sweeney; Robert Cook; Andrew A Wagner; William C DeWolf; Glenn J Bubley; Renee Funches; Joseph A Aronovitz; John T Wei; Martin G Sanda
Journal:  J Urol       Date:  2011-07-23       Impact factor: 7.450

10.  Iris morphologic changes related to alpha(1)-adrenergic receptor antagonists implications for intraoperative floppy iris syndrome.

Authors:  Tiago Santos Prata; Pat-Michael Palmiero; Allison Angelilli; Zaher Sbeity; Carlos Gustavo V De Moraes; Jeffrey M Liebmann; Robert Ritch
Journal:  Ophthalmology       Date:  2009-05       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.